DTx Neuroglee raises $10 million to deal with neurodegenerative illnesses

A Boston-based startup is trying to assist deal with neurodegenerative illness with a smartphone-based digital therapeutic known as Neuroglee.

This morning the startup received a lift when it closed a $10 million Sequence A spherical led by Openspace Ventures with participation from EDBI, Eisai Co and particular person buyers. 

Numerous methods have been demonstrated to gradual or enhance cognitive impairment in Alzheimer’s illness,” Aniket Singh Rajput, CEO of Neuroglee, informed MobiHealthNews in an e mail.

“Whereas nearly all of this work has been demonstrated within the hospital setting in inpatient applications, we had a dream of bringing that sort of remedy to sufferers in their very own houses – particularly to these sufferers who aren’t close to a medical heart of excellence with any such program.

“We’ll now have the ability to try this by working with sufferers’ clinicians throughout the nation by way of our digital care and digital remedy options.”


Neuroglee Therapeutics is at the moment specializing in sufferers with delicate cognitive impairments, akin to early stage Alzheimer’s. Its know-how consists of three most important parts: an app for sufferers, an app for caregivers and a web-based portal for clinicians. 

The affected person app features a slew of interventions, together with memory remedy, which makes use of pictures from a affected person’s previous to evoke feelings and reminiscences, cognitive video games, studying modules, and wellness modules that embody thoughts and physique workouts. 

“The digital affected person instrument employs participating gamification methods and cognitive duties on a smartphone or pill in order that sufferers’ clinicians can remotely monitor their cognitive operate and intervene utilizing customized cognitive rehabilitation methods,” Rajput stated in an e mail.

“Neuroglee’s machine-learning algorithms personalize every affected person’s remedy by robotically adjusting, or titrating, the therapeutic mobile-based actions based mostly on a number of novel digital biomarkers tied to cognitive operate, temper and habits.”

Caregivers are capable of entry an app that enables them to watch the affected person’s care and monitor adherence, in addition to talk with the affected person just about. 

“An vital facet of Neuroglee’s platform is that it isn’t only for sufferers {and professional} clinicians, but in addition for sufferers’ households, who’re most frequently the caregivers within the residence,” Rajput stated. “A regarding statistic is that 76% of the caregivers for folks with Alzheimer’s illness report that their very own well being has worsened as they’ve cared for a member of the family.

“That’s the reason Neuroglee has a separate caregiver module that helps them handle their member of the family with a neurodegenerative situation, but in addition affords schooling, help and instruments for figuring out and overcoming the stress, nervousness and different signs that may have an effect on caregivers.”

Equally, docs and nurses will have the ability to entry a dashboard that displays a affected person’s progress. The dashboard lets clinicians monitor a affected person’s cognition over time. 

At present Neuroglee is an investigational product in a proof of idea research. The startup plans to hunt an FDA Breakthrough designation after the research is accomplished. 

The startup is teaming up with the Mayo Clinic to co-develop Neuroglee Join, a medical care program that may incorporate the Mayo Clinic’s Wholesome Motion to Profit Independence & Considering (HABIT) and Neuroglee’s “adaptive studying platform.” As a part of the collaboration, sufferers will have the ability to faucet into 24/7 well being navigators and medical care groups for assessments and interventions. 


The corporate plans to make use of the brand new infusion of money in the direction of constructing its digital therapeutic. 

“​​The funding will primarily assist us additional develop our first line of digital care options and digital therapeutics for treating delicate cognitive impairment associated to difficult-to-treat neurodegenerative situations akin to Alzheimer’s illness, whereas additionally advancing further digital therapeutics in our pipeline.

“On the similar time, the funding will assist us full the mandatory analysis, verifications and documentation for incomes a Breakthrough System designation from the FDA for our digital therapeutic answer,” Rajput stated in an e mail. 

The corporate additionally plans to make use of the brand new money to develop Neuroglee Join and transfer its operations from Singapore to Boston. 


This isn’t the primary digital therapeutic to take a look at neurodegenerative situations. In 2018, San Diego-based Dthera Sciences landed an FDA Breakthrough System designation. Nevertheless, by 2021, the corporate had dissolved. 

The corporate’s CEO Ed Cox stated that restricted CMS reimbursement and quite a few candidate-drug failures amongst potential companions severed Dthera’s commercialization plan. 

Nevertheless, there are a number of digital therapeutics which have made it to the market. In 2017, Pear Therapeutics’ ReSET landed an FDA de novo to deal with substance use dysfunction. Since then, Pear landed quite a few different FDA clearances. Lately it went public by way of a $1.6 billion SPAC merger with Thimble Level Acquisition


Supply hyperlink

What's your reaction?

In Love
Not Sure

You may also like

More in:Health

Leave a reply

Your email address will not be published. Required fields are marked *